Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) is an established treatment for hematologic malignancies resistant to conventional chemotherapy. Acute graft-versus-host disease (aGVHD) is the major complication of patients who receive allogeneic grafts. 1 It is now well established that mature T cells present in grafts initiate the aGVHD reaction when they are activated by the host major or minor alloantigens. Indeed, depletion of the T cells in graft reduced the incidence of aGVHD, but increased the rate of relapse, providing evidence of the role of donor-type T cells in the graft-versus-leukemia effect. 2, 3 It has been suggested that most of the clinical manifestations of aGVHD are due to cytokine dysregulation. The murine model has provided strong evidence for the existence of a link between excessive or dysregulated cytokine production and aGVHD. 4 Several studies have demonstrated that mature CD4 þ T cells and CD8 þ T cells polarize into two subsets with different cytokine production profiles, including type 1 (interleukin(IL)-2, interferon(IFN)g) and type 2 (IL-4, IL-10). [5] [6] [7] [8] The different activation of these two subsets determines the character of an ensuing immune response, and IL-12 plays a central role in the activation of type 1 cytokines. 9 It has been recently suggested that such a polarization plays an important role in the development of aGVHD.
There have been several studies analyzing the involvement of different cytokines in the course of aGVHD after allogeneic bone marrow transplantation. [10] [11] [12] In this study, we examined the cytokine mRNA expression at the onset of aGVHD, using reverse transcription-polymerase chain reaction (RT-PCR), and also measured cytokine concentrations in medium from PHA-or LPS-stimulated cell cultures during allo-PBSCT, and we focused on both type 1 (IL-2, IFNg) and type 2 (IL-4, IL-10) cytokines, and on IL-12 and IL-18 expression.
Patients and methods

Patients
The subjects were 30 patients who underwent allogeneic PBSCT at our hospital from January 1999 to February 2001: 16 patients with chronic myelogenous leukemia (CML-CP), six patients with acute myelogenous leukemia (AML) (three patients with AML-M5, two patients with M4, one patient with M2), six patients with acute lymphoblastic leukemia (ALL) (five patients with ALL-L2, one with ALL-L1), one patient with severe aplastic anemia (SAA) and one patient with non-Hodgkin's lymphoma (NHL-IVB). The mean age of patients was 37 years (ranging from 18 to 49 years), and there were 11 females and 19 males ( Table 1 ). The conditioning regimen was CTX þ VP16 þ TBI (CTX at a dose of 120 mg/kg, VP16 at 20 mg/kg, and TBI at 7-9 Gy). For GVHD prophylaxis, the basic treatment was cyclosporin A (CsA, 2 mg/kg/day) starting at day À1, and short-course methotrexate (15 mg/m 2 at day 1 and 10 mg/m 2 at days 3, 6 and 11).
Collection of peripheral blood mononuclear cells (PBMC)
Recipient blood samples (5-10 ml) were collected before PBSCT and on day 30 after PBSCT. In patients developing aGVHD, PBMC were collected within 24-48 h of aGVHD clinical manifestations. Before administering specific treatment, mononuclear cells were isolated using FicollHypaque, snap-frozen and stored at À701C until RNA isolation.
RNA and cDNA preparations
Total RNA was extracted from PBMC according to a modified guanidine thiocyanate-phenol-chloroform extraction method. 13 cDNA was prepared by RT for 1 mg of total RNA in 10 ml of DEPC water using Moloney murine leukemia virus reverse transcriptase (200 U/ml). Then, 4 ml of 5 Â buffer (250 mM Tris-HCl, pH 8.3; 250 mM KCl; 50 mM DTT, Promega), 2 ml of 0.1 M dithiothreitol, 1 ml of Rnase inhibitor, 1 ml of 10 mM dNTP, 1 ml of oligo-dT (Promega, 0.5 mg/ml) and 1 ml of reverse transcriptase (Promega) were added to the RNA in a final volume of 20 ml. After incubation (371C, 30 min; 991C, 5 min), the mixture was stored at 41C until used.
Polymerase chain reaction
Sequence-specific primers were chosen to amplify DNA fragments of defined size for the cytokine genes of interest ( Table 2 ). The 2 ml aliquots of the synthesized cDNA were added to a reaction mixture containing 1.5 mM MgCl 2 , 2.5 ml 10 Â buffer (100 mM KCl, 80 mM [NH 4 ] 2 SO 4 , 100 mM Tris-HCl, 0.8% NP-40), 0.2 mM of 10 mM dNTP (AMRE-SO), 10 pmol of each primer and 1.25 U of Taq polymerase (Promega) and DEPC water in a final volume of 25 ml. All the samples were overlaid with 20 ml of mineral oil (Sigma) and incubated in a thermal cycler ( Table 3 ). The presence of the product was assessed by 2% agrose gel electrophoresis. PBMC isolated from a healthy volunteer incubated with rhIL-2 and PHA (25 mg/ml) for 24 h were used as positive controls for IL-2, IL-4, IL-10 and IFN-g, and PBMC incubated with LPS (30 mg/ml) were used as positive controls for IL-12 and IL-18. Negative controls consisted of PCR reaction mixtures without cDNA subjected to the same amplification program as the experimental specimens. Additionally, the constitutively expressed gene b-actin was evaluated in each sample to test the integrity of the cDNA as well as to verify the comparability of RNA input for each cDNA synthesis.
Cytokine concentration secreted by PBMC
Peripheral blood was collected at the following times: before PBSCT, at the onset of aGVHD and when symptoms of aGVHD were controlled. PBMC were cultured at 10 6 /ml in RPMI-1640 medium containing 10% fetal calf serum for 12 h at 371C in 5% CO 2 /air; to the medium PHA (25 mg/ml) and LPS (30 mg/ml) were added to measure IFN-g, IL-2, IL-4 and IL-10, and IL-12 and IL-18, respectively. Then, cells were harvested and washed twice with PBS, and were assayed by the ELISA kit (Genzyme, USA). The sensitivity of the cytokines assay was 10 pg/ml.
Statistical analysis
Results were presented as the mean7s.e.m. The significance of differences between the two groups was determined using Student's t-test. The w 2 test was used for comparison of cytokine mRNA expression in PBMC specimens with or without aGVHD.
Results
Patient characteristics
All patients achieved rapid hematopoietic engraftment; white cell engraftment (ANC 40.5 Â 10 9 /ml) occurred at a median of 17 days. Among the 30 patients, seven patients developed moderate-severe GVHD grade II-IV, seven patients had grade I GVHD and 16 had no GVHD.
Type 1 cytokine expression
Before PBSCT, cytokine mRNA of IFN-g, IL-2, IL-4, IL-10 and IL-12 could be detected in no patients in this study. After PBSCT, IFN-g mRNA could be detected in all patients with grade II-IV GVHD (100%), in six patients with grade I GVHD (85.7%) and only in one patient without aGVHD (6.25%). So, IFN-g mRNA increased in patients with aGVHD. IL-2 mRNA could be detected in six patients with grade II-IV GVHD (85.7%), in six with grade I GVHD (85.7%) and in two patients without aGVHD (12.5%). The positive rate of IL-2 mRNA increased in patients with aGVHD (Table 1, Figure 1 ). IFN-g and IL-2 concentration in culture supernatants of PBMC stimulated with PHA was significantly higher in patients with aGVHD after PBSCT (IFN-g concentration during aGVHD, grade 0, 412.27103.7 pg/ml; grade I, 928.47158.6 pg/ml; grade II-IV, 1112.67126.6 pg/ml and IL-2 concentration during aGVHD, grade 0, 613.07171.1 pg/ml; grade I, 1018.47178.4 pg/ml; grade II-IV, 1359.17206.9 pg/ml). The level of IFN-g, IL-2 concentration increased in parallel with increasing severity of aGVHD and decreased when symptoms of aGVHD were controlled (Figures 2 and 3 ).
Type 2 cytokine expression
IL-4 mRNA could be detected in three patients with grade II-IV GVHD (42.9%), in three with grade I GVHD (42.9%) and in seven without aGVHD (43.8%). So, IL-4 mRNA did not differ between patients with or without aGVHD. IL-10 mRNA could be detected in no patients with grade II-IV GVHD, in one with grade I GVHD (14.3%) and in 15 patients without aGVHD (93.8%). So, IL-10 mRNA increased in patients without aGVHD (Table 1, Figure 1 ). In culture supernatants of PBMC stimulated with PHA, the IL-4 concentration increased in patients without aGVHD after PBSCT, decreased when grade II-IV GVHD was present and showed no change in patients with grade I GVHD (IL-4 concentration during aGVHD, grade 0, 1008.57142.6 pg/ml; grade I, 555.67172.1 pg/ml; grade II-IV, 344.97100.1 pg/ml; Figure 4 ). The IL-10 concentration was significantly higher in patients without aGVHD after PBSCT, decreased in patients with aGVHD and increased when symptoms of aGVHD were controlled (IL-10 concentration during aGVHD, grade 0, 1038.07188.2 pg/ml; grade I, 221.27105.2 pg/ml; grade II-IV, 277.27105.1 pg/ml) ( Figure 5 ). Figure 1 ). IL-12 concentration in culture supernatants of PBMC stimulated with LPS was significantly higher in patients with aGVHD after PBSCT. The level of IL-12 concentration increased in parallel with increasing severity of aGVHD and decreased when symptoms of aGVHD were controlled (IL-12 concentration during aGVHD, grade 0, 576.57145.2 pg/ml; 
IL-18 concentration
We only tested IL-18 concentration secreted by PBMC stimulated with LPS after PBSCT. IL-18 concentration increased when aGVHD occurred, parallel with severity of aGVHD, and decreased when symptoms of aGVHD were controlled. In patients without aGVHD, IL-18 concentration showed no change before and after PBSCT (IL-18 concentration during aGVHD, grade 0, 555.77182.2 pg/ml; grade I, 804.7773.3 pg/ml; grade II-IV, 1359.97228.3 pg/ml) ( Figure 7 ).
Discussion
Allogeneic PBSCT is associated with serious side effects, the most common of which is GVHD. The use of unrelated donors and HLA-nonidentical family members has resulted in increased frequencies of severe GVHD. 14 Despite a 10-fold increase in T-cell dose, the incidence and severity of aGVHD following allogeneic transplantation of G-CSF-mobilized PBSC does not increase compared to BMT. Experimental murine studies demonstrate that G-CSF polarizes donor T cells toward a type 2 cytokine response. 15 Recently, we have measured the concentration of several cytokines in the serum of patients after allogeneic hematopoietic stem cell transplantation, including soluble interleukin-2 receptor (sIL-2R), IL-6, IL-8 and tumor necrosis factor-a (TNF-a). Results showed that sIL-2R levels increased during aGVHD and that the increase of sIL-2R levels in serum preceded the clinical signs of aGVHD. Other serum cytokine concentrations could not be detected after transplantation by ELISA. 16 In this study, we examined the cytokine mRNA expression and cytokine concentration secreted by PBMC at the onset of aGVHD. Results showed an increased gene expression of IL-2, IFN-g and IL-12 in PBMC collected from patients at the onset of aGVHD, and also showed an increased concentration of IL-2, IFN-g, IL-12 and IL-18 secreted by PBMC after stimulated with PHA or LPS. We believe that the cells responding to tissue histoincompatibility antigens might circulate in the blood before invading the target organs of aGVHD. It has been confirmed that cytokines in PBMC parallel the cytokine profile in skin with GVHD. 17 Current evidence suggests that dysregulated cytokine production occurs as a cascade during sequential monocyte and T-cell activation and is responsible for many of the manifestations of acute GVHD. 18 These mechanisms have been most clearly delineated in mouse BMT models. The conditioning regimen leads to damage and activation of host tissues and induces the secretion of the inflammatory cytokines. These cytokines increase the expression of major histocompatibility complex antigens by mature donor T cells and lead to the formation of bacterial breakdown product such as LPS. LPS may subsequently stimulate splanchnic or circulating monocyte-macrophages (MF) to produce IL-12.
19 Donor T cells are activated and secreted IL-2 and IFN-g, inducing T-cell expansion and cytotoxic T lymphocytes and NK cell responses, and priming monocytes to produce proinflammatory responses and proinflammatory cytokines. There is much evidence to implicate IL-2 and IFN-g as pivotal mediators of aGVHD, IL-4 and IL-10 produced by activated type 2 T cells prevent the secretion of IFN-g. Although results obtained in experimental aGVHD models in mice validated this hypothesis, the involvement of cytokines in human aGVHD is not clearly established. Detailed analysis is required.
Some studies have shown cytokine dysregulation in the pathogenesis of clinical aGVHD. Tanaka et al 10 reported that levels of IFN-g detected in vitro in mixed leukocyte culture between donor and host PBMC correlated with GVHD development in the corresponding patients. Roy et al 17 examined the cytokine mRNA expression in the PBMC and skin biopsy of allo-BMT patients. IL-2, IL-4 and IFN-g expression was more frequently detectable in PBMC and in skin biopsies after the development of aGVHD. However, other investigators have failed to establish a good correlation between Th1-type cytokines with human aGVHD. Carayol et al 12 used quantitative PCR to examine the transcription of genes encoding cytokines in PBMC and skin biopsies after allo-BMT. In PBMC, higher levels of IFN-g mRNA were observed in aGVHD þ patients at the beginning of aGVHD. In skin biopsies samples, neither type 1(IL-2, IFN-g) nor type 2 (IL-4, IL-10) cytokines could be detected.
Our data indicate that transcription of type 1 cytokines is significantly more frequent in PBMC at the onset of aGVHD after allo-PBSCT, and the concentration secreted by PBMC in a stimulated medium significantly increased. The cellular origins of the observed IL-2, IFN-g transcription might be CD8 þ T cells, because most immunophenotyping studies have shown a predominance of CD8 þ T cells within GVHD lesions; these cells might well be the direct source of these mediators. 20 In this study, we also found that the production of IL-10 was lower during aGVHD. IL-10 was initially described as a cytokine synthesis inhibitory factor; [21] [22] [23] it strongly inhibits the antigen-specific proliferative responses of T cells. 24 Baker et al 25 used an ELISA method to assay IL-10 concentration secreted by PBMC in a medium containing LPS. Results suggested that high spontaneous IL-10 production in unrelated bone marrow transplant recipients was associated with fewer transplant-related complications including aGVHD. Takatsuka et al 26 found an association between marked elevation of plasma IL-10 in the recovery after BMT and severe aGVHD. Lin et al 27 analyzed singlenucleotide polymorphisms located in genes for IL-1b, IL-1RA, IL-6, IL-10 and TNF-a in 570 transplant recipients and their HLA-identical sibling donors. Results showed that the recipient's IL-10 promoter region genotype was significantly associated with the risk of aGVHD and the IL-10-592A/A genotype was associated with a decreased risk of grade III or IV aGVHD. A haplotype analysis showed that recipients homozygous for the IL-10 T-C-A-T-A haplotype had a lower risk of aGVHD. Together with the reported biologic function of IL-10 in vitro and in vivo, 28, 29 data suggested that T-C-A-T-A haplotype was defined by high levels of IL-10. This study supports the hypothesis that a high level of IL-10 production by recipients' cell during the early post transplantation period reduces the clinical manifestations of aGVHD. Although we found no difference between controls and aGVHD patients for IL-4 transcription, a role for IL-4 gene expression in the aGVHD cascade is not excluded and could be further explored using quantitative PCR. Our data showed that the concentration of IL-4 secreted by PBMC stimulated with PHA decreased in patients with grade II-IV GVHD.
We also investigated IL-12 and IL-18 concentration secreted by PBMC stimulated with LPS and IL-12 mRNA. Our data showed that the levels of IL-12 and IL-18 were elevated in patients with aGVHD. Yabe et al 19 investigated IFN-g production by peripheral blood lymphocytes from allogeneic stem cell recipients after IL-12 plus anti-CD3 monoclone antibody stimulation, and also investigated IL-12 production by peripheral macrophages after LPS stimulation. IFN-g and IL-12 production increased in patients with aGVHD, which suggested that IL-12 plays an important role in the development of human aGVHD, and that activation of Th1 cells is primarily responsible for initiating aGVHD. IL-18 is a cytokine with wide-ranging biological functions that include activation not only of innate immunity but also of acquired immunity, including both Th1 responses, particularly in collaboration with IL-12, and Th2 responses. 30 Fujimori et al 31 showed that the serum concentration of IL-18 elevated in patients with aGVHD. In aGVHD, the Fas/FasL system plays an essential role in the development of fatal tissue injuries. It is confirmed in a mouse model of aGVHD that IL-18 is secreted in a FasL-initiated, caspase-1-dependent manner. 32 In summary, the major finding of this study is that IFNg, IL-2, IL-12 and IL-18 are significantly more frequent in patients with aGVHD. We believe that a better understanding of the secreting cells and the sequence of cytokine release may allow the design of more effective therapies for aGVHD and improve the outcome of allo-PBSCT. Further investigation is needed to clarify the exact relationship of aGVHD to cytokines, especially with regard to the role of PBMC, and a large-scale study is needed to analyze cytokine expression during GVHD. However, our present study may help to provide some clues to the roles of cytokines in pathogenesis of human aGVHD after allo-PBSCT.
